A 24-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Effect of LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril; Valsartan
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARALLAX
- Sponsors Novartis; Novartis Pharmaceuticals
- 05 Nov 2018 Planned End Date changed from 29 Jan 2019 to 4 Dec 2019.
- 05 Nov 2018 Planned primary completion date changed from 29 Jan 2019 to 4 Dec 2019.
- 03 Oct 2018 Planned number of patients changed from 2200 to 2500.